B Taylor Thompson. The Lancet, Early Online Publication, 12 December 2011
In The Lancet , Fang Gao Smith and the BALTI-2 study investigators 1 report the findings of their phase-3 randomised trial of intravenous salbutamol for acute respiratory distress syndrome (ARDS). The trial, based on reliable preclinical evidence and an encouraging phase-2 trial, was stopped early because of safety concerns. 2
β-agonists had been an appealing therapeutic option for ARDS in view of extensive clinical experience, low cost, and an excellent safety profile when used for patients with obst …
Weblink here